Importantly, compared with the patients with residual tumors, the pCR patients have achieved superior long-term survival, especially for those with human epidermal growth factor receptor 2 (HER2) positive and triple negative breast cancers (4–7). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.